GUARDANT HEALTH INC (GH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for GH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GH | Lead Independent Director; Chair | 65 | ["Former Chief Executive Officer of Genentech Inc.","14 years at Genentech including 12 on the Executive Committee","20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle","Advisor to KKR and previously at Lazard, Blackstone Life Sciences, and Perella Weinberg Partners","Served on the Board of the Biotechnology Industry Organization (BIO)","Member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve","Chair of the External Advisory Board to Southampton University’s Institute for Life Sciences","B.Sc. and honorary doctorate in biological sciences from Southampton University"] | ["Nominating and Corporate Governance Committee (Chair)"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OLMA | Chairperson of the Board | 65 | [] | ["Compensation"] | 2026 |
Biography sourced from the proxy statement filing.
Ian Clark has served as a member of our Board since January 2017 and is our lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe and France. Mr. Clark currently serves on the Board of Directors of Takeda Pharmaceutical Company Limited, Olema Pharmaceuticals, Inc., Kyverna Therapeutics Inc, Corvus Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. In June 2026, Mr. Clark will end his service on the Board of Directors of Takeda Pharmaceutical Company Limited, and has communicated to the Company s Board his intent to further reduce his board service in 2026. He previously served on the Board of Directors of Shire Pharmaceuticals, Kite Pharma, Gyroscope, Forty Seven, Agios, Dendreon, Vernalis, AVROBIO, Inc. and GoodRx Holdings, Inc. Mr. Clark is an advisor to KKR and was previously an advisor at Lazard, Blackstone Life Sciences, and Perella Weinberg Partners. He served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. He also served on the BioFulcrum Board of the Gladstone Institute and as Chair of the External Advisory Board to Southampton University s Institute for Life Sciences. Mr. Clark received a B.Sc. and an honorary doctorate in biological sciences from Southampton University. We believe that Mr. Clark is qualified to serve as a member of our Board due to his vast experience in the biopharmaceutical industry, combined with his experience serving on the boards of directors of successful, high-growth public and private companies.